165 - Novel Strategies to Diagnose, Monitor, Treat and Prevent Hepatitis B and Hepatitis D

Tuesday, October 21, 2025

1:45 PM - 3:00 PM US ET

Location: B308-B309

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Harrys Torres, MD

Professor
Infectious Diseases/ Gastroenterology, Hepatology, and Nutrition
The University of Texas MD Anderson Cancer Center
Houston, TX, United States
Susanna Naggie, MD/MHS (she/her/hers)

Professor of Medicine
Duke University School of Medicine
Durham, NC, United States

Faculty(s)

Ashwin Balagopal, MD (he/him/his)

Associate Professor of Medicine
Johns Hopkins School of Medicine
Anna Lok, MD (she/her/hers)

Professor
University of Michigan
Ann Arbor, MI, United States
Tarik Asselah, MD PhD (he/him/his)

Professor of Hepatology, Head of Viral Hepatitis
Université de Paris-Cité. Hôpital Beaujon, Paris, France., France

Disclosure(s):

Harrys A. Torres, MD: National Cancer Institute, and Gilead Sciences,: Grant/Research Support

Susanna Naggie, MD/MHS: BMS/PRA: Event Adjudication Committee; Clinical Infectious Diseases: Deputy Editor; Vir Biotechnologies: Stocks/Bonds (Public Company)

Ashwin Balagopal, MD: QuidelOrtho: Advisor/Consultant

Anna Lok, MD: Brii Biosciences: Advisor/Consultant; Chroma: Advisor/Consultant; Grifols: Advisor/Consultant; Moderna: Advisor/Consultant; Pfizer, Inc.: Advisor/Consultant; Pioneering: Advisor/Consultant; Precision Biosciences: Advisor/Consultant; Roche Molecular Systems, Inc.: Advisor/Consultant; Virion: Advisor/Consultant; Zenasbio: Advisor/Consultant

Tarik Asselah, MD PhD: AbbVie: Advisor/Consultant, Board Member, Grant/Research Support, Honoraria; Aligos Therapeutics: Advisor/Consultant, Board Member, Grant/Research Support, Honoraria; Antios Therapeutics: Advisor/Consultant, Honoraria; Bluejay: Advisor/Consultant, Board Member, Grant/Research Support, Honoraria; Gilead Sciences: Advisor/Consultant, Board Member, Grant/Research Support, Honoraria; GSK: Advisor/Consultant, Board Member, Grant/Research Support, Honoraria; Vir Biotechnology: Advisor/Consultant, Board Member, Grant/Research Support, Honoraria

Learning Objectives:

At the conclusion of this session, participants will be able to:

discuss the testing and monitoring guidelines for clinicians and laboratorians regarding hepatitis B and hepatitis D;
describe the novel therapies aimed at reducing hepatitis B replication or antigen load, as well as immunotherapeutic strategies;
explain the diagnosis, management, and new treatments of hepatitis D;
discuss strategies for preventing hepatitis B and hepatitis D.

Presentations:

1:45 PM - 2:10 PM US ET

Hepatitis B: Update on Vaccination, Noninvasive Fibrosis Staging and When to Start and When to Stop Treatment
Speaker: Anna Lok, MD (she/her/hers) – University of Michigan
2:10 PM - 2:35 PM US ET

Update on Hepatitis B Treatment Pipeline
Speaker: Ashwin Balagopal, MD (he/him/his) – Johns Hopkins School of Medicine
2:35 PM - 3:00 PM US ET

Hepatitis D Chronic Infection: Current and Future Treatments
Speaker: Tarik Asselah, MD PhD (he/him/his) – Université de Paris-Cité. Hôpital Beaujon, Paris, France.